KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash & Equivalents (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Cash & Equivalents for 17 consecutive years, with $8.5 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 11.9% to $8.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 billion through Dec 2025, up 11.9% year-over-year, with the annual reading at $8.5 billion for FY2025, 11.9% up from the prior year.
  • Cash & Equivalents hit $8.5 billion in Q4 2025 for Abbott Laboratories, up from $7.5 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $9.9 billion in Q4 2022 to a low of $6.3 billion in Q1 2024.
  • Historically, Cash & Equivalents has averaged $8.0 billion across 5 years, with a median of $7.8 billion in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 138.5% in 2021 and later crashed 31.4% in 2024.
  • Year by year, Cash & Equivalents stood at $9.8 billion in 2021, then rose by 0.85% to $9.9 billion in 2022, then plummeted by 30.22% to $6.9 billion in 2023, then increased by 10.44% to $7.6 billion in 2024, then increased by 11.9% to $8.5 billion in 2025.
  • Business Quant data shows Cash & Equivalents for ABT at $8.5 billion in Q4 2025, $7.5 billion in Q3 2025, and $7.0 billion in Q2 2025.